0.94
-0.0149(-1.57%)
Currency In USD
| Previous Close | 0.95 |
| Open | 0.95 |
| Day High | 0.95 |
| Day Low | 0.9 |
| 52-Week High | 3.41 |
| 52-Week Low | 0.85 |
| Volume | 667,509 |
| Average Volume | 615,820 |
| Market Cap | 43.64M |
| PE | -1.03 |
| EPS | -0.91 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 1.26 |
| Change | -0.01 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) 10 years ago, it would be worth $2.84 as of November 02, 2025 at a share price of $0.935. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $451.74 as of November 02, 2025 at a share price of $0.935.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWS
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
GlobeNewswire Inc.
Oct 29, 2025 12:37 PM GMT
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s Proposed Amendment to Ongoing VERSATILE-003 Trial
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
GlobeNewswire Inc.
Sep 18, 2025 12:45 PM GMT
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy signal observe